Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

New Findings for Polymyalgia Rheumatica & Osteoarthritis

Ruth Jessen Hickman, MD  |  December 1, 2022

The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2022OsteoarthritisPolymyalgia Rheumaticasarilumabweight loss

Almost Half of Patients with RA Experience Flare after Glucocorticoid Discontinuation

Lara C. Pullen, PhD  |  October 25, 2022

In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.

Filed under:ConditionsRheumatoid Arthritis Tagged with:discontinuationflareglucocorticoidRA flaresRheumatoid Arthritis (RA)

Image Case Report: Milk of Urate Bulla

Samantha C. Shapiro, MD  |  October 10, 2022

A 60-year-old Black woman with a history of stage 3 chronic kidney disease, type 2 diabetes and hypertension presented with a 12-month history of asymmetric polyarthritis of the wrists, metacarpophalangeal (MCP), proximal interphalangeal (PIP), metatarsophalangeal (MTP) and knee joints. The review of systems was unremarkable. She denied oral ulcers, rashes, alopecia, or a history of…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:case reportGoutmilk of urate bulla

Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

Michael Putman, MD  |  September 27, 2022

In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)guidelineVasculitis

An Evidence-Based Drug Update & Guidance for Rheumatologists

Samantha C. Shapiro, MD  |  August 14, 2022

ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…

Filed under:Drug UpdatesEducation & TrainingMeeting ReportsOther ACR meetings Tagged with:AAV FocusRheumACR Education ExchangeU.S. Food and Drug Administration (FDA)

A Vessel for Knowledge: The Latest Research & Management Updates for Vasculitis

Jason Liebowitz, MD, FACR  |  August 11, 2022

Brendan Antiochos, MD, provided a timely update on research and treatments related to vasculitis, addressing treatments for ANCA-associated vasculitis and giant cell arteritis, COVID-19 vaccination and more.

Filed under:ConditionsMeeting ReportsVasculitis Tagged with:Annual Advances in the Diagnosis & Treatment of the Rheumatic DiseasesavacopanGCAgiant cell arteritis (GCA)mavrilimumabVasculitis

Just in Case: Understanding Rheumatoid Arthritis Through Patient Cases

Jason Liebowitz, MD, FACR  |  August 11, 2022

Uzma Haque, MD, addressed the management of difficult-to-treat rheumatoid arthritis, using patient case reports to demonstrate clinical decision-making, during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseasespatient careRheumatoid Arthritis (RA)

Refractory Gout Is a Myth: Tips from an Expert

Samantha C. Shapiro, MD  |  July 22, 2022

At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.

Filed under:ConditionsEULAR/OtherGout and Crystalline ArthritisMeeting Reports Tagged with:EULARGoutGout Resource Centerpatient carerefractory gout

Difficult-to-Treat Lupus: When & How to Use New Therapies

Samantha C. Shapiro, MD  |  July 21, 2022

Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabEULARHCQHydroxychloroquine (HCQ)rituximabSLEsystemic lupus erythematosus (SLE)

Biologic or Conventional Therapy for Early RA?

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.

Filed under:Biologics/DMARDsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:Biologicsearly RAEULARRheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences